Abstract
Identification of clinically meaningful subphenotypes of disease progression can facilitate better understanding of disease heterogeneity and underlying pathophysiology. We propose a machine learning algorithm, termed dynaPhenoM, to achieve this goal based on longitudinal patient records such as electronic health records (EHR) or insurance claims. Specifically, dynaPhenoM first learns a set of coherent clinical topics from the events across different patient visits within the records along with the topic transition probability matrix, and then employs the time-aware latent class analysis (T-LCA) procedure to characterize each subphenotype as the evolution of these learned topics over time. The patients in the same subphenotype have similar such topic evolution patterns. We demonstrate the effectiveness and robustness of dynaPhenoM on the case of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) progression on three patient cohorts, and five informative subphenotypes were identified which suggest the different clinical trajectories for disease progression from MCI to AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
FW acknowledges the support from NIH RF1AG072449 and NSF 1750326. JC is supported by National Center for Advancing Translational Sciences (NCATS) Grant (UL1TR001998). JB is supported by National Institutes of Health (NIH) Grants (R21 AG068717, R01CA246418-02S1, R56AG069880). FC is supported by NIH U01AG073323, R01AG066707 and R56AG074001.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1. The University of Florida institutional review board under number IRB202000704 gave ethical approval for this work about the analysis on OneFlorida data; 2. The University of Kentucky CCTS Enterprise Data Center institutional review board under number 43542 gave ethical approval for this work about the analysis on MarketScan data; 3. The institutional review board under number IRB-19-02369 gave ethical approval for this work about the analysis on Mount Sinai data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
